Absci Corp

  • Health Care
  • Biotechnology: Commercial Physical & Biological Resarch
  • www.absci.com
  • Moat Score
  • Safety Score
  • Market Cap $350.99M
  • PE -4
  • Debt $3.27M
  • Cash $55.15M
  • EV $299.11M
  • FCF -$70.76M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$97.67M
EBIT-$96.56M
ROE-49%
ROA-41%
FCF-$70.76M
Equity$201.34M
Growth Stability1
PE-3.59
PB1.74
P/FCF-4.96
P/S83.43
Price/Cash0.16
Debt/Equity0.02
Debt/FCF-0.05
Net Margins-2K%
Op. Margins-2K%
Sales Growth YoY129%
Sales Growth QoQ34%
Sales CAGR-4%
Equity CAGR-18%
Earnings Growth YoY25%
Earnings Growth QoQ11%
Sales CAGR 5Y-4%
Equity CAGR 5Y-18%
Earnings CAGR 3Y-4%
Sales CAGR 3Y-4%
Equity CAGR 3Y-20%
Market Cap$350.99M
Revenue$4.21M
Assets$235.23M
Total Debt$3.27M
Cash$55.15M
Shares Outstanding108.67M
EV299.11M
Moat Score1%
Safety Score65%
Working Capital123.46M
Current Ratio5.63
Shares Growth 3y5%
Equity Growth QoQ-9%
Equity Growth YoY3%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

SEC Filings

Direct access to Absci Corp (ABSI) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Absci Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Absci Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Absci Corp Discounted Cash Flow

Fully customizable DCF calculator online for Absci Corp.

= -$708M
012345678910TV
fcf-$71M-$71M-$71M-$71M-$71M-$71M-$71M-$71M-$71M-$71M-$71M-$708M
DCF-$64M-$58M-$53M-$48M-$44M-$40M-$36M-$33M-$30M-$27M-$273M
Value-$708M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/202012/202112/202212/2023TTM
Net Margins-1K%-2K%-2K%-2K%-2K%
ROA--18%-33%-50%-41%
ROE--28%-38%-63%-49%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/202012/202112/202212/2023TTM
Debt over FCF--0.06-0.16-0.18-0.05
Debt over Equity-0.010.020.060.070.02
Growth Stability----1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-0%20%-1%-4%
Earnings YoY growth-109%2%5%-
Equity YoY growth--509%-25%-36%-18%
FCF YoY growth-650%-1%-33%-